Compare AbbVie Inc (ABBV) vs ASML Holding NV (ASML) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ASML Holding NV — how do they compare? AbbVie Inc trades at $254.14 (market cap $449.91B), while ASML Holding NV trades at $1,776.23 (market cap $662.67B). The key difference: ASML Holding NV is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | ASML | |
|---|---|---|
Market Cap | $449.91B | $662.67B |
Sector | Health | Technology |
52-Week High | $261.07 | $1.99K |
52-Week Low | $184.85 | $689.63 |
Enterprise Value | $513.38B | $656.21B |
Dividend Yield | 2.72% | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
ASML trades at $1,747.28, down 1.25% amid semiconductor sector volatility. The stock shows strong fundamentals with 2025 revenue of $32.67B and net income of $9.61B, supported by robust profitability margins. Technical indicators are neutral, with support near $1,748. Recent news highlights AI-driven demand and geopolitical risks in chip supply chains.
Outlook remains positive given ASML's monopoly in EUV lithography and analyst consensus price target of $2,210. Risks include cyclical semiconductor demand and geopolitical tensions. Earnings beat in Q1 2026 reinforces growth trajectory, but high valuations require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →
